Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTA NASDAQ:IRON NASDAQ:MESO NASDAQ:OPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$16.08-4.3%$13.96$9.10▼$19.09$2.25B1.481.08 million shs1.38 million shsIRONDisc Medicine$59.79+1.4%$54.00$30.82▼$68.73$2.04B0.77349,805 shs306,418 shsMESOMesoblast$15.43+1.7%$12.26$5.78▼$22.00$1.94B2.4314,351 shs56,714 shsOPTOpthea$3.41+7.2%$3.41$1.79▼$6.30$524.84M1.17N/A3,000 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals-4.34%+5.79%+12.17%+34.04%+59.68%IRONDisc Medicine+1.39%+0.52%+9.22%+39.98%+39.57%MESOMesoblast+1.71%-3.14%+43.00%+41.37%+144.15%OPTOpthea0.00%0.00%0.00%0.00%+51.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTACentessa Pharmaceuticals3.0455 of 5 stars3.53.00.00.02.03.30.6IRONDisc Medicine3.4085 of 5 stars4.53.00.00.02.62.50.0MESOMesoblast0.7658 of 5 stars2.51.00.00.00.00.80.6OPTOptheaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 3.00Buy$28.1074.75% UpsideIRONDisc Medicine 3.08Buy$95.7360.11% UpsideMESOMesoblast 3.00Buy$18.0016.66% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideCurrent Analyst Ratings BreakdownLatest OPT, IRON, MESO, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.007/21/2025CNTACentessa PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.007/21/2025IRONDisc MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.007/21/2025IRONDisc MedicineTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$86.007/18/2025MESOMesoblastJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold7/3/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$85.007/3/2025IRONDisc MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$118.006/17/2025IRONDisc MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$118.006/16/2025IRONDisc MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.006/11/2025IRONDisc MedicineRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$89.005/28/2025CNTACentessa PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.00(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$6.85M313.67N/AN/A$3.05 per share5.27IRONDisc MedicineN/AN/AN/AN/A$14.85 per shareN/AMESOMesoblast$5.90M334.75N/AN/A$4.21 per share3.67OPTOpthea$120K4,373.61N/AN/A($0.56) per share-6.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$235.76M-$1.81N/AN/AN/AN/A-40.22%-29.95%8/12/2025 (Estimated)IRONDisc Medicine-$109.36M-$3.92N/AN/AN/AN/A-22.61%-21.07%8/6/2025 (Estimated)MESOMesoblast-$87.96MN/A0.00N/AN/AN/AN/AN/A8/27/2025 (Estimated)OPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/A8/29/2025 (Estimated)Latest OPT, IRON, MESO, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/27/2025H2 2025MESOMesoblast-$0.20N/AN/AN/A$7.48 millionN/A8/14/2025Q2 2025IRONDisc Medicine-$1.17N/AN/AN/AN/AN/A8/12/2025Q2 2025CNTACentessa Pharmaceuticals-$0.34N/AN/AN/AN/AN/A5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.2814.3714.37IRONDisc Medicine0.0437.6537.65MESOMesoblast0.220.960.63OPTOptheaN/A1.57N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%IRONDisc Medicine83.70%MESOMesoblast1.43%OPTOpthea55.95%Insider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals7.09%IRONDisc Medicine4.24%MESOMesoblast18.80%OPTOpthea3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200133.62 million124.15 millionOptionableIRONDisc Medicine3034.63 million33.17 millionNot OptionableMESOMesoblast80128.00 million103.93 millionOptionableOPTOpthea8153.91 million148.99 millionNot OptionableOPT, IRON, MESO, and CNTA HeadlinesRecent News About These CompaniesOpthea (NASDAQ:OPT) Stock Price Up 7.2% - What's Next?July 26, 2025 | marketbeat.comBiocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expectedJuly 2, 2025 | msn.comOpthea Faces Leadership Changes Amidst Clinical Trial SetbacksJune 1, 2025 | tipranks.comBiotech Dimerix lands $940m licensing deal for kidney drug salesMay 1, 2025 | afr.comPhil King’s Regal successfully bets against Tesla, NvidiaMay 1, 2025 | afr.com'No one is happy': Regal stockpickers face financial hit after Opthea blow upApril 21, 2025 | capitalbrief.comCRegal’s King says his hedge funds will recover from March madnessApril 16, 2025 | afr.comRegal: Don’t catch the falling knife, wait for it to stick in the floorApril 16, 2025 | msn.comOpthea to lay off approximately 65% of companyApril 10, 2025 | ophthalmologytimes.comOOpthea lays off 65% of staff after back-to-back phase 3 eye disease flopsApril 10, 2025 | fiercebiotech.comFBELL POTTER SECURITIES Downgrades Opthea (CKDXF)April 9, 2025 | msn.comBELL POTTER SECURITIES Downgrades Opthea Limited - Depositary Receipt () (OPT)April 9, 2025 | msn.comASX drops as US jumbo China tariff takes effectApril 9, 2025 | afr.comOpthea Limited (CKDXF) was downgraded to a Sell Rating at Bell PotterApril 3, 2025 | markets.businessinsider.comPhil King’s Regal writes Opthea to zero and backs off risky betsApril 2, 2025 | afr.comOpthea Ends Development of Sozinibercept in Wet AMDMarch 31, 2025 | marketwatch.comLifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drugMarch 31, 2025 | endpts.comEOpthea terminates COAST trial, announces ShORe trial misses endpointMarch 31, 2025 | markets.businessinsider.comOpthea scraps wet AMD program after eye drug loses out to Lucentis in latest phase 3 failMarch 31, 2025 | fiercebiotech.comFOpthea discontinues development of sozinibercept in wet AMDMarch 31, 2025 | healio.comHOpthea Announces Decision to Discontinue Wet AMD TrialsMarch 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Rocket Lab: A Parabolic Run Meets a Healthy PullbackBy Ryan Hasson | July 23, 2025View Rocket Lab: A Parabolic Run Meets a Healthy PullbackPelosi Makes Big Bet on Broadcom—Here’s Why It MattersBy Gabriel Osorio-Mazilli | July 15, 2025View Pelosi Makes Big Bet on Broadcom—Here’s Why It MattersPalantir Gets Price Hike From Wedbush Amid High ValuationBy Chris Markoch | July 15, 2025View Palantir Gets Price Hike From Wedbush Amid High ValuationPalantir Bulls and Bears Set for an August Showdown By Chris Markoch | July 22, 2025View Palantir Bulls and Bears Set for an August Showdown OPT, IRON, MESO, and CNTA Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$16.08 -0.73 (-4.34%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$16.32 +0.24 (+1.49%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Disc Medicine NASDAQ:IRON$59.79 +0.82 (+1.39%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$59.76 -0.02 (-0.04%) As of 08/4/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Mesoblast NASDAQ:MESO$15.43 +0.26 (+1.71%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$15.46 +0.04 (+0.23%) As of 08/4/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Opthea NASDAQ:OPT$3.41 +0.23 (+7.23%) As of 08/1/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How 2 Deals in 48 Hours Changed Everything for Joby Aviation Here's Why Traders Turned Bullish on Boeing Stock Onsemi’s August Pullback Is a Signal to Buy for Tech Investors Strategy Insiders Buy In While Analysts Predict Big Upside Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging Yes, You Can Get Dividends in Tech: 3 Stocks With Yield + Upside MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
